Philippe Laffont, Coatue founder and portfolio manager, joins 'Squawk Box' to discuss the latest market trends, state of the 'Magnificent Seven', future of tech investing, his thoughts on bitcoin, state of the economy, impact of AI technology, who'll come on top in the AI arms race, the Fed's interest rate policy, future of TikTok, the NYC mayoral race, and more. ...

With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell affiliated hospitals, thus laying a solid foundation for my current expertise. As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Va ...

I'm going to address the both of you guys again. Let's back up and talk about tech investing more broadly in the context of what else has been dominating the markets, which is this rapidly changing geopolitical landscape. Todd, I'll go to you for this one.We've seen a good amount of volatility around some of the recent developments on the geopolitical front, specifically when it comes to conflict in the Middle East. It has been jarring for sure, but interestingly enough uh not as jarring from a straight qua ...

Group 1 - The article discusses Tiziana Life Sciences (NASDAQ: TLSA) and its ongoing drug development efforts, particularly focusing on the Foralumab drug and its additional Expanded Access Program (EAP) enrollment [2] - The author is affiliated with Biotech Analysis Central, which provides extensive analysis and resources for healthcare investors, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2] - The service offered by Biotech Analysis Central is priced at $49 per month, with a yearly plan available at a discounted rate of $399, representing a 33.50% discount [1] Group 2 - The article does not provide specific financial data or performance metrics related to Tiziana Life Sciences or its products [4] - There are no disclosed positions or plans to initiate positions in the companies mentioned, indicating a neutral stance from the author [3]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth?Moderna (NASDAQ: MRNA ) shares are down over 35% year-to-date, over 80% on a one-year basis, and since reaching their pandemic era high of over $450 per share, they are down 94%.The group is for both novice and expe ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Both my spouse and I have a DPhil from Oxford University. Mine is in Cell Physiology and his is in Bio-organic Chemistry. Growing wealth sustainably is our goal. Investing in R&D biotech is our focus. My articles and comments are not financial advice, as I am not a financial adviser. I wrote SA articles for readers who find reading & considering SA articles helpful to their own research. All the best in seeking & finding alpha through biotech investing!Analyst’s Disclosure: I/we have a beneficial long posit ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Today, we are going to put Omnicell, Inc. ( OMCL ) , a small-cap medical technology solutions provider in the spotlight for the first time. The company just posted its Q1 results o ...